Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05352035

Multiomics Tumor Evolution Model of NSCLC

The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-small Cell Lung Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Lung cancer is the leading cause of cancer-related death globally. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and surgery is still the main treatment strategy. This study will determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old;
  • Early-stage NSCLC patients underwent radical surgical resection;
  • Sufficient tumor tissue and blood sample for study use;
  • Available clinical-pathologic data, imaging data and follow-up date;
  • Written informed consent.

Exclusion criteria

  • History of other malignant tumors;
  • Evidence of distant metastasis before surgery;
  • Insufficient tumor tissue or blood sample for study use;
  • Clinical-pathologic data, imaging data or follow-up date is not available;
  • Other judgments by the Investigator that the patient should not participate in the study.

Treatment and study plan

Primary outcomes

  1. Disease-free survival (DFS)

    Time frame: Through study completion, an average of 2 years

    Time from randomization to disease recurrence or death from any cause.

  2. Overall survival (OS)

    Time frame: Through study completion, an average of 2 years

    Time from randomization to death from any cause.

Secondary outcomes

  1. Relationship between translational biomarkers and clinical outcome

    Time frame: Through study completion, an average of 2 years

    To evaluate if the translational biomarkers can be prediction tools for the clinical outcomes.

Study contacts

Contact information is provided by the study sponsor or research team.

Kezhong Chen, M.D.

CONTACT

[email protected]

+86-010-88326657

Wenxiang Wang

CONTACT

[email protected]

+86-010-88326657

Sponsors and collaborators

Lead sponsor

Peking University People's Hospital

Other

Collaborators

  • Chinese Academy of Medical Sciences

Registry information

Official study title

A Multiomics Study of Tumor Evolution Characteristics and Prognostic Model in Early-stage Non-small Cell Lung Cancer

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Apr 28, 2022
Registry last updated
Apr 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.